SIM 0317
Alternative Names: SIM-0317Latest Information Update: 26 Apr 2022
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Rad51 recombinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Apr 2022 Preclinical trials in Cancer in China (unspecified route), before April 2022 (Simcere Pharmaceuticals pipeline, April 2022)